

Neuronetics, Inc. Supplemental Financial and Operating Information

For the period ended June 30, 2020

| Revenue (\$ thousands) | 2018 | | | | 2019 | | | | 2020 | 2020 | 2018 | 2019 |
|--|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|----------------|-----------------|-----------------|
| | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | FY | FY |
| NeuroStar Capital (1) | \$1,909 | \$3,268 | \$3,428 | \$4,338 | \$2,939 | \$4,034 | \$4,264 | \$4,959 | \$2,410 | \$2,224 | \$12,942 | \$16,196 |
| YoY Change | 76% | 65% | 54% | 47% | 54% | 23% | 24% | 14% | -18% | -45% | 57% | 25% |
| NeuroStar Operating Lease (2) | \$258 | \$181 | \$269 | \$231 | \$182 | \$187 | \$184 | \$177 | \$155 | \$114 | \$939 | \$730 |
| YoY Change | 13% | -38% | -7% | -2% | -29% | 3% | -31% | -24% | -15% | -39% | -10% | -22% |
| Other (3) | \$206 | \$120 | \$211 | \$185 | \$229 | \$407 | \$167 | \$278 | \$29 | \$0 | \$722 | \$1,081 |
| YoY Change | NM | -50% | -34% | -35% | 11% | 239% | -21% | 50% | -87% | -100% | -15% | 50% |
| Total U.S. NeuroStar Advanced Therapy System Revenues | \$2,373 | \$3,568 | \$3,908 | \$4,754 | \$3,350 | \$4,628 | \$4,616 | \$5,413 | \$2,594 | \$2,338 | \$14,603 | \$18,007 |
| YoY Change | 80% | 42% | 38% | 37% | 41% | 30% | 18% | 14% | -23% | -49% | 44% | 23% |
| Total U.S. Treatment Sessions Revenues | \$7,240 | \$8,920 | \$9,218 | \$9,909 | \$8,778 | \$10,847 | \$10,252 | \$11,243 | \$8,193 | \$6,547 | \$35,287 | \$41,120 |
| YoY Change | 26% | 21% | 28% | 23% | 21% | 22% | 11% | 13% | -7% | -40% | 24% | 17% |
| Total U.S. Other Revenues | \$359 | \$410 | \$392 | \$426 | \$418 | \$415 | \$426 | \$374 | \$390 | \$382 | \$1,587 | \$1,633 |
| YoY Change | 11% | 25% | 15% | 21% | 16% | 1% | 9% | -12% | -7% | -8% | 19% | 3% |
| Total U.S. Revenues | \$9,972 | \$12,898 | \$13,518 | \$15,089 | \$12,546 | \$15,890 | \$15,294 | \$17,030 | \$11,177 | \$9,267 | \$51,477 | \$60,760 |
| YoY Change | 35% | 26% | 30% | 27% | 26% | 23% | 13% | 13% | -11% | -42% | 29% | 18% |
| Total International Revenues | \$180 | \$354 | \$219 | \$546 | \$182 | \$682 | \$706 | \$326 | \$299 | \$474 | \$1,299 | \$1,896 |
| YoY Change | 36% | 325% | 137% | 100% | 1% | 93% | 222% | -40% | 64% | -30% | 124% | 46% |
| Total Revenues | \$10,152 | \$13,252 | \$13,737 | \$15,635 | \$12,728 | \$16,572 | \$16,000 | \$17,356 | \$11,476 | \$9,741 | \$52,776 | \$62,656 |
| YoY Change | 35% | 29% | 31% | 29% | 25% | 25% | 16% | 11% | -10% | -41% | 31% | 19% |
| Operating and Financial Metrics | 2018 | | | | 2019 | | | | 2020 | 2020 | 2018 | 2019 |
| | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | FY | FY |
| Active Installed Base | | | | | | | | | | | | |
| Active Installed Base - Beginning of Period | 752 | 781 | 816 | 858 | 907 | 931 | 976 | 1,032 | 1,085 | 1,119 | 752 | 907 |
| Active Installed Base - End of Period | 781 | 816 | 858 | 907 | 931 | 976 | 1,032 | 1,085 | 1,119 | 1,122 | 907 | 1,085 |
| Total NeuroStar Systems Sold (4) | 24 | 43 | 47 | 61 | 43 | 61 | 68 | 78 | 38 | 35 | 175 | 250 |
| YoY Change | 71% | 72% | 57% | 53% | 79% | 42% | 45% | 28% | -12% | -43% | 61% | 43% |
| Average Revenue Per Active System (\$ (5)) | \$9,627 | \$11,421 | \$11,297 | \$11,549 | \$9,678 | \$11,651 | \$10,504 | \$10,895 | \$7,552 | \$5,850 | \$46,924 | \$45,337 |
| YoY Change | 8% | 4% | 8% | 4% | 1% | 2% | -7% | -6% | -22% | -50% | 7% | -3% |

(1) = Revenue from Capital Sales and Sales Type Leases

(2) = Revenue derived from Operating Lease revenue during the period

(3) = Primarily includes revenue derived from Treatment Coils in US

(4) = Includes all systems sold during the period, both as Capital Sales or Sales-Type-Leases

(5) = Total Treatment Session Revenue / Active Installed Base (End of Prior Period)